The new face of bispecific antibodies: targeting cancer and much more.

摘要: The term magic bullet was first coined by bacteriologist Paul Ehrlich in the late 1800s to describe a chemical with ability specifically target microorganisms while sparing normal host cells. His concept later expanded include treatments for cancer, but it is only recent decades, development and improvements monoclonal antibody (mAb) technology, that full therapeutic implications of "magic bullet" strategies have been realized. Expanding on success mAb-targeting, linking specificity two mAbs into single agent, called bispecific (BiAb), allows targeting biological agent or cell specific tissue antigens. Classically, BiAbs used several decades redirect cytotoxic T cells other effector kill tumor Here, we review preclinical models ongoing phase I clinical trials which arming polyclonally activated may provide anti-tumor activity without dose-limiting toxicities. Additionally, findings from this novel strategy merges technology hematopoietic stem repair injured myocardium. Arming directed at injury-associated antigens enhances homing engraftment myocardial infarctions significantly improve cardiac function, strongly suggesting new paradigms BiAb-targeting applications repair.